Risk-based centralized data monitoring of clinical trials at the time of COVID-19 pandemic

被引:9
|
作者
Afroz, Most Alina [1 ]
Schwarber, Grant [2 ]
Bhuiyan, Mohammad Alfrad Nobel [2 ]
机构
[1] Begum Rokeya Univ, Dept Elect & Elect Engn, Rangpur, Bangladesh
[2] Medpace Inc, Dept Biostat, 5375 Medpace Way, Cincinnati, OH 45227 USA
关键词
Centralize data monitoring; Risk based data monitoring; DATA QUALITY;
D O I
10.1016/j.cct.2021.106368
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Objectives: COVID-19 pandemic caused several alarming challenges for clinical trials. On-site source data verification (SDV) in the multicenter clinical trial became difficult due to travel ban and social distancing. For multicenter clinical trials, centralized data monitoring is an efficient and cost-effective method of data monitoring. Centralized data monitoring reduces the risk of COVID-19 infections and provides additional capabilities compared to on-site monitoring. The key steps for on-site monitoring include identifying key risk factors and thresholds for the risk factors, developing a monitoring plan, following up the risk factors, and providing a management plan to mitigate the risk. Methods: For analysis purposes, we simulated data similar to our clinical trial data. We classified the data monitoring process into two groups, such as the Supervised analysis process, to follow each patient remotely by creating a dashboard and an Unsupervised analysis process to identify data discrepancy, data error, or data fraud. We conducted several risk-based statistical analysis techniques to avoid on-site source data verification to reduce time and cost, followed up with each patient remotely to maintain social distancing, and created a centralized data monitoring dashboard to ensure patient safety and maintain the data quality. Conclusion: Data monitoring in clinical trials is a mandatory process. A risk-based centralized data review process is cost-effective and helpful to ignore on-site data monitoring at the time of the pandemic. We summarized how different statistical methods could be implemented and explained in SAS to identify various data error or fabrication issues in multicenter clinical trials.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] On the Risk-based Contagion of G7 Banking System and the COVID-19 Pandemic
    Matos, Paulo
    Costa, Antonio
    da Silva, Cristiano
    GLOBAL BUSINESS REVIEW, 2024, 25 (06) : 1634 - 1654
  • [32] Data Quarantine in the Time of the COVID-19 Pandemic
    Shah, Rashmee U.
    Curtis, Lesley H.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2020, 13 (06): : 277 - 279
  • [33] Risk-Based Monitoring in Clinical Trials: Past, Present, and Future
    Brian Barnes
    Nicole Stansbury
    Debby Brown
    Lauren Garson
    Geoff Gerard
    Nickolas Piccoli
    Debra Jendrasek
    Nick May
    Vanesa Castillo
    Anina Adelfio
    Nycole Ramirez
    Andrea McSweeney
    Ruth Berlien
    Paula Jo Butler
    Therapeutic Innovation & Regulatory Science, 2021, 55 : 899 - 906
  • [34] Risk-Based Monitoring in Clinical Trials: Past, Present, and Future
    Barnes, Brian
    Stansbury, Nicole
    Brown, Debby
    Garson, Lauren
    Gerard, Geoff
    Piccoli, Nickolas
    Jendrasek, Debra
    May, Nick
    Castillo, Vanesa
    Adelfio, Anina
    Ramirez, Nycole
    McSweeney, Andrea
    Berlien, Ruth
    Butler, Paula Jo
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2021, 55 (04) : 899 - 906
  • [35] COVID-19 interventional trials: Analysis of data sharing intentions during a time of pandemic
    Larson, Kristina
    Sim, Ida
    von Isenburg, Megan
    Levenstein, Marcia
    Rockhold, Frank
    Neumann, Stan
    D'Arcy, Catherine
    Graham, Elizabeth
    Zuckerman, David
    Li, Rebecca
    CONTEMPORARY CLINICAL TRIALS, 2022, 115
  • [36] An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
    Daniel Beever
    Lizzie Swaby
    Trials, 20
  • [37] An evaluation of risk-based monitoring in pragmatic trials in UK Clinical Trials Units
    Beever, Daniel
    Swaby, Lizzie
    TRIALS, 2019, 20 (01)
  • [38] The Impact of the COVID-19 Pandemic on Oncology Care and Clinical Trials
    Ali, Jennyfa K.
    Riches, John C.
    CANCERS, 2021, 13 (23)
  • [39] The impact of COVID-19 pandemic on vascular registries and clinical trials
    Aziz, Faisal
    Behrendt, Christian-Alexander
    Sullivan, Kaity
    Beck, W. Adam
    Beiles, C. Barry
    Boyle, R. Jon
    Mani, Kevin
    Benson, A. Ruth
    Wohlauer, V. Max
    Khashram, Manar
    Jorgensen, Jens Eldrup
    Lemmon, W. Gary
    SEMINARS IN VASCULAR SURGERY, 2021, 34 (02) : 28 - 36
  • [40] Statistical Evaluation of Clinical Trials Under COVID-19 Pandemic
    Chow, Shein-Chung
    Zhang, Wei
    THERAPEUTIC INNOVATION & REGULATORY SCIENCE, 2020, 54 (06) : 1551 - 1556